Quantitative imaging in cancer clinical trials

Thomas E. Yankeelov, David A. Mankoff, Lawrence H. Schwartz, Frank S. Lieberman, John M. Buatti, James M. Mountz, Bradley J Erickson, Fiona M M Fennessy, Wei Huang, Jayashree Kalpathy-Cramer, Richard L.Wahl, Hannah M. Linden, Paul E. Kinahan, Binsheng Zhao, Nola M. Hylton, Robert J. Gillies, Laurence Clarke, Robert Nordstrom, Daniel L. Rubin

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

As anticancer therapies designed to target specific molecular pathways have been developed, it has become critical to develop methods to assess the response induced by such agents. Although traditional, anatomic CT, and MRI examinations are useful in many settings, increasing evidence suggests that these methods cannot answer the fundamental biologic and physiologic questions essential for assessment and, eventually, prediction of treatment response in the clinical trial setting, especially in the critical period soon after treatment is initiated. To optimally apply advances in quantitative imaging methods to trials of targeted cancer therapy, new infrastructure improvements are needed that incorporate these emerging techniques into the settings where they are most likely to have impact. In this review, we first elucidate the needs for therapeutic response assessment in the era of molecularly targeted therapy and describe how quantitative imaging can most effectively provide scientifically and clinically relevant data. We then describe the tools and methods required to apply quantitative imaging and provide concrete examples of work making these advances practically available for routine application in clinical trials. We conclude by proposing strategies to surmount barriers to wider incorporation of these quantitative imaging methods into clinical trials and, eventually, clinical practice. Our goal is to encourage and guide the oncology community to deploy standardized quantitative imaging techniques in clinical trials to further personalize care for cancer patients and to provide a more efficient path for the development of improved targeted therapies.

Original languageEnglish (US)
Pages (from-to)284-290
Number of pages7
JournalClinical Cancer Research
Volume22
Issue number2
DOIs
StatePublished - Jan 15 2016

Fingerprint

Clinical Trials
Neoplasms
Therapeutics
Patient Care

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yankeelov, T. E., Mankoff, D. A., Schwartz, L. H., Lieberman, F. S., Buatti, J. M., Mountz, J. M., ... Rubin, D. L. (2016). Quantitative imaging in cancer clinical trials. Clinical Cancer Research, 22(2), 284-290. https://doi.org/10.1158/1078-0432.CCR-14-3336

Quantitative imaging in cancer clinical trials. / Yankeelov, Thomas E.; Mankoff, David A.; Schwartz, Lawrence H.; Lieberman, Frank S.; Buatti, John M.; Mountz, James M.; Erickson, Bradley J; Fennessy, Fiona M M; Huang, Wei; Kalpathy-Cramer, Jayashree; L.Wahl, Richard; Linden, Hannah M.; Kinahan, Paul E.; Zhao, Binsheng; Hylton, Nola M.; Gillies, Robert J.; Clarke, Laurence; Nordstrom, Robert; Rubin, Daniel L.

In: Clinical Cancer Research, Vol. 22, No. 2, 15.01.2016, p. 284-290.

Research output: Contribution to journalArticle

Yankeelov, TE, Mankoff, DA, Schwartz, LH, Lieberman, FS, Buatti, JM, Mountz, JM, Erickson, BJ, Fennessy, FMM, Huang, W, Kalpathy-Cramer, J, L.Wahl, R, Linden, HM, Kinahan, PE, Zhao, B, Hylton, NM, Gillies, RJ, Clarke, L, Nordstrom, R & Rubin, DL 2016, 'Quantitative imaging in cancer clinical trials', Clinical Cancer Research, vol. 22, no. 2, pp. 284-290. https://doi.org/10.1158/1078-0432.CCR-14-3336
Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM et al. Quantitative imaging in cancer clinical trials. Clinical Cancer Research. 2016 Jan 15;22(2):284-290. https://doi.org/10.1158/1078-0432.CCR-14-3336
Yankeelov, Thomas E. ; Mankoff, David A. ; Schwartz, Lawrence H. ; Lieberman, Frank S. ; Buatti, John M. ; Mountz, James M. ; Erickson, Bradley J ; Fennessy, Fiona M M ; Huang, Wei ; Kalpathy-Cramer, Jayashree ; L.Wahl, Richard ; Linden, Hannah M. ; Kinahan, Paul E. ; Zhao, Binsheng ; Hylton, Nola M. ; Gillies, Robert J. ; Clarke, Laurence ; Nordstrom, Robert ; Rubin, Daniel L. / Quantitative imaging in cancer clinical trials. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 2. pp. 284-290.
@article{4ea78948189b471b82a6b78ecb5eac44,
title = "Quantitative imaging in cancer clinical trials",
abstract = "As anticancer therapies designed to target specific molecular pathways have been developed, it has become critical to develop methods to assess the response induced by such agents. Although traditional, anatomic CT, and MRI examinations are useful in many settings, increasing evidence suggests that these methods cannot answer the fundamental biologic and physiologic questions essential for assessment and, eventually, prediction of treatment response in the clinical trial setting, especially in the critical period soon after treatment is initiated. To optimally apply advances in quantitative imaging methods to trials of targeted cancer therapy, new infrastructure improvements are needed that incorporate these emerging techniques into the settings where they are most likely to have impact. In this review, we first elucidate the needs for therapeutic response assessment in the era of molecularly targeted therapy and describe how quantitative imaging can most effectively provide scientifically and clinically relevant data. We then describe the tools and methods required to apply quantitative imaging and provide concrete examples of work making these advances practically available for routine application in clinical trials. We conclude by proposing strategies to surmount barriers to wider incorporation of these quantitative imaging methods into clinical trials and, eventually, clinical practice. Our goal is to encourage and guide the oncology community to deploy standardized quantitative imaging techniques in clinical trials to further personalize care for cancer patients and to provide a more efficient path for the development of improved targeted therapies.",
author = "Yankeelov, {Thomas E.} and Mankoff, {David A.} and Schwartz, {Lawrence H.} and Lieberman, {Frank S.} and Buatti, {John M.} and Mountz, {James M.} and Erickson, {Bradley J} and Fennessy, {Fiona M M} and Wei Huang and Jayashree Kalpathy-Cramer and Richard L.Wahl and Linden, {Hannah M.} and Kinahan, {Paul E.} and Binsheng Zhao and Hylton, {Nola M.} and Gillies, {Robert J.} and Laurence Clarke and Robert Nordstrom and Rubin, {Daniel L.}",
year = "2016",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-14-3336",
language = "English (US)",
volume = "22",
pages = "284--290",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Quantitative imaging in cancer clinical trials

AU - Yankeelov, Thomas E.

AU - Mankoff, David A.

AU - Schwartz, Lawrence H.

AU - Lieberman, Frank S.

AU - Buatti, John M.

AU - Mountz, James M.

AU - Erickson, Bradley J

AU - Fennessy, Fiona M M

AU - Huang, Wei

AU - Kalpathy-Cramer, Jayashree

AU - L.Wahl, Richard

AU - Linden, Hannah M.

AU - Kinahan, Paul E.

AU - Zhao, Binsheng

AU - Hylton, Nola M.

AU - Gillies, Robert J.

AU - Clarke, Laurence

AU - Nordstrom, Robert

AU - Rubin, Daniel L.

PY - 2016/1/15

Y1 - 2016/1/15

N2 - As anticancer therapies designed to target specific molecular pathways have been developed, it has become critical to develop methods to assess the response induced by such agents. Although traditional, anatomic CT, and MRI examinations are useful in many settings, increasing evidence suggests that these methods cannot answer the fundamental biologic and physiologic questions essential for assessment and, eventually, prediction of treatment response in the clinical trial setting, especially in the critical period soon after treatment is initiated. To optimally apply advances in quantitative imaging methods to trials of targeted cancer therapy, new infrastructure improvements are needed that incorporate these emerging techniques into the settings where they are most likely to have impact. In this review, we first elucidate the needs for therapeutic response assessment in the era of molecularly targeted therapy and describe how quantitative imaging can most effectively provide scientifically and clinically relevant data. We then describe the tools and methods required to apply quantitative imaging and provide concrete examples of work making these advances practically available for routine application in clinical trials. We conclude by proposing strategies to surmount barriers to wider incorporation of these quantitative imaging methods into clinical trials and, eventually, clinical practice. Our goal is to encourage and guide the oncology community to deploy standardized quantitative imaging techniques in clinical trials to further personalize care for cancer patients and to provide a more efficient path for the development of improved targeted therapies.

AB - As anticancer therapies designed to target specific molecular pathways have been developed, it has become critical to develop methods to assess the response induced by such agents. Although traditional, anatomic CT, and MRI examinations are useful in many settings, increasing evidence suggests that these methods cannot answer the fundamental biologic and physiologic questions essential for assessment and, eventually, prediction of treatment response in the clinical trial setting, especially in the critical period soon after treatment is initiated. To optimally apply advances in quantitative imaging methods to trials of targeted cancer therapy, new infrastructure improvements are needed that incorporate these emerging techniques into the settings where they are most likely to have impact. In this review, we first elucidate the needs for therapeutic response assessment in the era of molecularly targeted therapy and describe how quantitative imaging can most effectively provide scientifically and clinically relevant data. We then describe the tools and methods required to apply quantitative imaging and provide concrete examples of work making these advances practically available for routine application in clinical trials. We conclude by proposing strategies to surmount barriers to wider incorporation of these quantitative imaging methods into clinical trials and, eventually, clinical practice. Our goal is to encourage and guide the oncology community to deploy standardized quantitative imaging techniques in clinical trials to further personalize care for cancer patients and to provide a more efficient path for the development of improved targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=84958750599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958750599&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-3336

DO - 10.1158/1078-0432.CCR-14-3336

M3 - Article

VL - 22

SP - 284

EP - 290

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -